HSIC

Business profile & competitive position

Henry Schein, Inc. sits in the Healthcare sector, specifically the Medical - Distribution industry. Its operations are organized into three reportable segments. Global Distribution and Value-Added Services supplies dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and related value-added services to office-based dental and medical practitioners plus alternate sites of care. Global Specialty Products manufactures and markets dental implants, biomaterials, endodontic, orthodontic, and orthopedic products. Global Technology develops and distributes practice management software, e-services, and technology-enabled products for healthcare providers.

The physical footprint is substantial: 38 distribution centers covering more than 5.4 million square feet, 17 manufacturing facilities covering 0.6 million square feet, more than 300,000 stocked products, roughly 150,000 cartons shipped daily, and 127 equipment sales and service centers worldwide. On the capital-efficiency side, ROE of 12.4% indicates the company is converting shareholder equity into reasonable returns despite a thin net margin. That thin margin—3.0%—is consistent with a distribution-heavy model where competition is fought over breadth, availability, logistics speed, and service rather than fat markups. The 12.4% ROE suggests scale, inventory turns, working-capital velocity, and recurring elements such as software subscriptions are helping offset the low margin. As of December 27, 2025, the Technology segment reported an active user base of approximately 95,000 practices and 324,000 consumers, a base that may help insulate the company from pure price competition in commodity-like distributed products.

Financial posture

Henry Schein currently has a market capitalization of $9.6 billion and trades at a P/E ratio of 24.3. That multiple is a meaningful premium to what is typical for pure-play healthcare distributors, though the valuation can partly be explained by the mix of software, specialty manufacturing, and value-added services embedded in the three segments. The 3.0% net margin confirms the distribution-heavy profit structure, while the 12.4% ROE shows the business is still generating double-digit equity returns. Beta of 0.81 implies the stock has historically moved somewhat less than the broad market, fitting a defensive, healthcare-services-oriented profile.

The posture reads as a stable, cash-conversion business rather than a high-multiple disruptor. Investors considering HSIC are left with the question of whether the 24.3 P/E is justified by the software, specialty, and services mix, or whether it leaves limited room for operational misses.

Strategic priorities & outlook

Henry Schein's most recent 10-K filing lays out a focused operational agenda. The company is executing what it calls the "BOLD+1" plan, which centers on building complementary software, specialty, and services businesses to drive higher-growth revenue streams beyond traditional distribution. This signals an intent to move up the value chain into areas with potentially better margins and more recurring revenue.

Near-term execution priorities include operationalizing "One Distribution," a program designed to improve customer experience while increasing efficiency and growth, and leveraging "One Schein" to broaden and deepen relationships with customers across the segments. Digital transformation is framed as a dual initiative: delivering technology solutions to customers while modernizing Henry Schein's own operations. The 95,000 active practice users and 324,000 consumers in the Technology segment provide a cross-selling base, though whether these initiatives can materially lift the 3.0% net margin remains an open operational question.

Macro & geopolitical exposure

As a Healthcare sector company in Medical - Distribution, Henry Schein operates at the intersection of regulated medical commerce and physical logistics. Relevant macro exposures include healthcare reimbursement policy, FDA and other regulatory compliance requirements for pharmaceuticals and medical devices, supply-chain and freight costs, and foreign-exchange risk tied to its global distribution and manufacturing footprint. Tariffs or trade restrictions on medical devices, implants, and orthopedic products could affect input costs or pricing in the Global Specialty Products segment. Inventory carrying costs, freight rates, and labor availability within the distribution network also matter. Because office-based practitioners are the key end customers, changes in dental and physician visit volumes, insurance reimbursement rates, and elective procedure demand can ripple through orders for both equipment and consumables.

Recent developments

Headlines surrounding Henry Schein in late September 2026 carried a generally positive tilt. On September 30, 2026, Business Wire reported that Henry Schein Cares marked 25 years under its "Helping Health Happen" initiative, highlighting long-running corporate responsibility efforts. On September 21, 2026, Zacks published "Here's Why Henry Schein (HSIC) is a Strong Growth Stock," reflecting a growth-oriented narrative. On September 19, 2026, Seeking Alpha ran "Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher," suggesting recent price momentum was drawing commentary. A day earlier, on September 18, 2026, Zacks asked, "Are Investors Undervaluing Henry Schein (HSIC) Right Now?"—indicating some observers viewed the stock as potentially inexpensive despite the 24.3 P/E. None of these are corporate disclosures, but together they show a narrative leaning toward growth and valuation optimism.

Earnings behavior & post-earnings drift

Henry Schein's recent earnings history is solid on beats but soft on post-release follow-through. Over the last eight reported quarters, HSIC beat earnings estimates six times, for a 75% beat rate, with an average earnings surprise of 2.9%. That means the company more often exceeds the market's real expectation than misses, though the typical beat is modest.

The post-earnings price action, however, tilts negative. Across those same eight quarters, the average 5-day price move after earnings was -2.05%, with the drift classified as "down." In other words, even when headline results beat estimates, the stock has on average given back ground over the subsequent trading days.

The last four quarters illustrate this dynamic. On August 4, 2026, Henry Schein reported $1.27 versus a $1.24 estimate, a 2.4% beat, and the stock rose 0.54% the next day and 0.08% over the next five days. On May 5, 2026, the company delivered a much larger 10.0% surprise—$1.32 versus $1.20—but the stock fell 2.6% the next day and 6.75% over the following five days. The February 24, 2026 report produced a 3.1% beat ($1.34 vs $1.30), yet the stock declined 1.73% the next day and 3.77% over five days. The November 4, 2025 quarter was an 8.7% beat ($1.38 vs $1.27), and the stock rose 0.56% the next day and 2.25% over five days, showing that strong beats can be rewarded but are not enough to reverse the broader negative drift statistic.

The next scheduled report arrives on November 3, 2026 before the open, with a consensus EPS estimate of $1.36. Given the 75% beat rate and 2.9% average surprise, a beat would fit recent history; the key question for the post-report price path is whether management's commentary and guidance can overcome the established 5-day negative drift.

For a deeper dive into how institutional analysts are interpreting Henry Schein's valuation, margin structure, and upcoming November 3, 2026 earnings report, review the full institutional verdict on the platform.